{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Cyclerion Therapeutics, Inc.
Is Cyclerion Therapeutics, Inc. overvalued or undervalued?
As of October 3, 2023, Cyclerion Therapeutics, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 15.2 and a price-to-book ratio of 1.8, outperforming peers and the Sensex.
Is Cyclerion Therapeutics, Inc. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data for Cyclerion Therapeutics, Inc. to determine a bullish or bearish outlook.
Who are in the management team of Cyclerion Therapeutics, Inc.?
As of March 2022, the management team of Cyclerion Therapeutics, Inc. includes Ms. Marsha Fanucci (Independent Chairman) and Dr. Peter Hecht (CEO), along with independent directors Mr. Kevin Churchwell, Mr. George Conrades, Dr. Ole Isacson, Ms. Stephanie Lovell, and Mr. Terrance McGuire. They are responsible for the company's strategic direction and governance.
What does Cyclerion Therapeutics, Inc. do?
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious and orphan diseases. As of March 2025, it reported net sales of $0 million and a net loss of $1 million, with a market cap of $9.97 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
